Locally Ablative Therapy for Oligo-Progressive Gastrointestinal Cancers (LIVELONG) Phase 2 Study Evaluating Addition of Local Ablative Treatments to Systemic Therapy

What this Trial Is About

This research focuses on patients with oligo-progressive solid tumors, including various gastrointestinal cancers such as esophageal, gastric, colorectal, biliary, and others. It evaluates whether continuing systemic therapy combined with locally ablative treatments can provide clinical benefit. The study is designed as a phase 2 pragmatic trial assessing disease control three months after ablative therapy, specifically looking for continued systemic therapy without changes or stopping treatment. Participants receive locally ablative therapies including stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation based on the treating physician's discretion, alongside their ongoing systemic cancer treatment. The study allows up to five years of follow-up after the initial ablative therapy to monitor outcomes. The treatments aim to target up to five progressing or new metastatic lesions safely treatable by these local methods. Throughout the study, participants will be closely monitored for disease control at three months post-ablative therapy, defined by continued systemic treatment without modification or discontinuation. Researchers will track the number of patients with controlled disease and overall time to treatment failure. To support safety and effectiveness assessments, participants must comply with all study procedures and remain available for the full study duration, ensuring comprehensive long-term data collection.

Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)